User profiles for "author:Helmut Butzkueven"
Helmut ButzkuevenMSNI Research Group, Dept of Neuroscience, School of Translational Medicine, Monash … Verified email at monash.edu Cited by 24105 |
[HTML][HTML] Brain health: time matters in multiple sclerosis
Introduction We present international consensus recommendations for improving diagnosis,
management and treatment access in multiple sclerosis (MS). Our vision is that these will be …
management and treatment access in multiple sclerosis (MS). Our vision is that these will be …
[HTML][HTML] Epigenome-wide association studies: current knowledge, strategies and recommendations
The aetiology and pathophysiology of complex diseases are driven by the interaction
between genetic and environmental factors. The variability in risk and outcomes in these …
between genetic and environmental factors. The variability in risk and outcomes in these …
Treatment decisions in multiple sclerosis—insights from real-world observational studies
The complexity of multiple sclerosis (MS) treatment means that doctors and decision-makers
need the best available evidence to make the best decisions for patient care. Randomized …
need the best available evidence to make the best decisions for patient care. Randomized …
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis
International IBD Genetics Consortium (IIBDGC)… - Nature …, 2013 - nature.com
Using the ImmunoChip custom genotyping array, we analyzed 14,498 subjects with multiple
sclerosis and 24,091 healthy controls for 161,311 autosomal variants and identified 135 …
sclerosis and 24,091 healthy controls for 161,311 autosomal variants and identified 135 …
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
Background No treatment has consistently shown efficacy in slowing disability progression
in patients with secondary progressive multiple sclerosis (SPMS). We assessed the effect of …
in patients with secondary progressive multiple sclerosis (SPMS). We assessed the effect of …
Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case-control study
IAF van der Mei, AL Ponsonby, T Dwyer, L Blizzard… - Bmj, 2003 - bmj.com
Objective To examine whether past high sun exposure is associated with a reduced risk of
multiple sclerosis. Design Population based case-control study. Setting Tasmania, latitudes …
multiple sclerosis. Design Population based case-control study. Setting Tasmania, latitudes …
Gait and balance impairment in early multiple sclerosis in the absence of clinical disability
CL Martin, BA Phillips, TJ Kilpatrick… - Multiple Sclerosis …, 2006 - journals.sagepub.com
This study evaluated the gait and balance performance of two clinically distinct groups of
recently diagnosed and minimally impaired multiple sclerosis (MS) patients (Expanded …
recently diagnosed and minimally impaired multiple sclerosis (MS) patients (Expanded …
Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis
JWL Brown, A Coles, D Horakova, E Havrdova… - Jama, 2019 - jamanetwork.com
Importance Within 2 decades of onset, 80% of untreated patients with relapsing-remitting
multiple sclerosis (MS) convert to a phase of irreversible disability accrual termed secondary …
multiple sclerosis (MS) convert to a phase of irreversible disability accrual termed secondary …
Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia
IAF van der Mei, AL Ponsonby, T Dwyer, L Blizzard… - Journal of …, 2007 - Springer
Abstract Background Adequate 25 (OH) D levels are required to prevent adverse effects on
bone health. Population-based data on factors associated with 25 (OH) D levels of people …
bone health. Population-based data on factors associated with 25 (OH) D levels of people …
Defining secondary progressive multiple sclerosis
J Lorscheider, K Buzzard, V Jokubaitis, T Spelman… - Brain, 2016 - academic.oup.com
A number of studies have been conducted with the onset of secondary progressive multiple
sclerosis as an inclusion criterion or an outcome of interest. However, a standardized …
sclerosis as an inclusion criterion or an outcome of interest. However, a standardized …